A
aTyr Pharma
ATyr Pharma | Brave Science | Meaningful Medicines
About aTyr Pharma
aTyr Pharma is a biopharmaceutical company focused on discovering and developing innovative therapeutics by harnessing newly discovered pathways in biology. The company primarily serves patients with severe and rare diseases, particularly those related to immune and fibrotic conditions. Operating in the biotechnology and pharmaceutical market, aTyr Pharma's business model revolves around research and development of first-in-class therapies, with a significant focus on their lead product candidate, Efzofitimod (ATYR1923), which is currently in Phase 3 clinical trials for pulmonary sarcoidosis. Revenue generation is primarily through partnerships, grants, and potential future product sales upon regulatory approval.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2005
- Headquarters
- San Diego, United States
- Listing
- IPO 2015
- Employees
- 75
- Open positions
- None listed
- Dealroom signal
- 33.8/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Client focus
- b2c
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITY✓Other financing | Mar 2026 | $0 | — | Undisclosed | ↗ |
| POST IPO EQUITY✓Other financing | Feb 2023 | $50M | — | Undisclosed | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for aTyr Pharma is 6.9K monthly website visits, down 11.5% over the last three months. aTyr Pharma's team declined 6.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Alta Partners
Polaris Partners
Series B and later6 investors entered at this stage
Domain Associates
Solar capital
Standard Treasury
Viking Global Investors
Redmile Group
EcoR1 Capital
Other known investors4 additional known investors
Scripps Translational Science Institute
Cardinal Partners
Sofinnova Investments
Sofinnova Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about aTyr Pharma on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See aTyr Pharma’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.